Sign In
Buy TNYA
$0.731
+0.0191 (+2.68%)
At Close: Jun 18, 2026
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
04:30pm, Tuesday, 18'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Tuesday, 14'th May 2024
Initial Data from Ongoing MyPEAK™ - 1 Phase 1b of TN-201 Expected in Second Half of 2024
Abstracts Demonstrate Tenaya's Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart Medicines Abstracts Demonstrate Tenaya's Continued
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Monday, 18'th Mar 2024
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
08:30am, Monday, 18'th Mar 2024
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
04:30pm, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
10:56am, Monday, 26'th Feb 2024
After reaching an important support level, Tenaya Therapeutics, Inc. (TNYA) could be a good stock pick from a technical perspective. TNYA recently experienced a "golden cross" event, which saw its 50-
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
11:20am, Sunday, 18'th Feb 2024
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
10:56am, Friday, 09'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is quest
Tenaya Therapeutics Announces Pricing of Underwritten Offering
08:00am, Thursday, 08'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
01:01pm, Friday, 26'th Jan 2024
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
08:30am, Wednesday, 03'rd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
04:30pm, Tuesday, 21'st Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US
